melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery inflammation/arthritis

Monocyte Infiltration
Monocyte infiltration into a site of injury or irritation is an integral part inflammatory process. Thioglycollate-mediated leukocyte recruitment and cytokine production in the peritoneum can be utilized as a model of inflammation, acute peritonitis and leukocyte/monocyte migration.  This system is an effective model for assessing a test compound's ability to interfere with these inflammatory processes.  However, compounds with varying mechanisms of action require a broad analysis of various cell types and chemicals produced during the inflammatory response. 

The inflammatory response generated in this model can be attenuated by administration of a number of known anti-inflammatory agents.  In this study, we utilized Dexamethasone treatment to test for effects on thioglycollate-stimulated production of peritoneal monocyte chemoattractant protein-1 (MCP-1). 

 

                           Monocyte inflammation MCP-1 levels

Administration of thioglycollate produced a dramatic increase in the levels of MCP-1 in vehicle-treated animals compared to untreated animals.   Treatment with dexamethasone, a potent corticosteroid, significantly reduced the levels of MCP-1 relative to vehicle treatment. This effect of dexamethasone is consistent with its anti-inflammatory activities and reported effects of compounds that reduce peritonitis in thioglycollate models (Segal et al., 2002).  Data represent mean concentrations ± SEM; **p<0.01 (compared to vehicle).

Dexamethasone was able to significantly reduce the levels of MCP-1 in the peritoneal cavity after thioglycollate administration.  This model stands as a good predictor of peritonitis anti-inflammatory compounds.  As a screen, it can point the way for further studies of promising compounds, in viewing relative levels of the cytokine MCP-1. 

 

If you are interested in learning more about Monocyte Inflammation, please contact models@meliordiscovery.com to start the conversation.